Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms- |
Target |
Action modulators |
Mechanism CLDN18.2 modulators(Claudin 18.2 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Bile Duct Carcinoma | Phase 1 | China | 01 Nov 2025 | |
| Advanced gastric carcinoma | Phase 1 | China | 01 Nov 2025 | |
| Advanced Gastroesophageal Junction Adenocarcinoma | Phase 1 | China | 01 Nov 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 01 Nov 2025 | |
| Advanced Pancreatic Adenocarcinoma | Phase 1 | China | 01 Nov 2025 |





